Eli Lilly and Company (NYSE:LLY) Shares Bought by Spinnaker Trust

Spinnaker Trust grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,524 shares of the company’s stock after acquiring an additional 16 shares during the period. Eli Lilly and Company comprises about 1.0% of Spinnaker Trust’s holdings, making the stock its 22nd biggest position. Spinnaker Trust’s holdings in Eli Lilly and Company were worth $14,878,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of LLY. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $26,000. Thompson Investment Management Inc. acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $27,000. Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $35,000. Optiver Holding B.V. acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $36,000. Finally, Family CFO Inc acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the sale, the insider now owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on LLY shares. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Barclays lifted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Bank of America lifted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research note on Monday, April 15th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Stock Up 1.2 %

NYSE:LLY traded up $8.64 on Friday, reaching $733.51. The stock had a trading volume of 1,998,801 shares, compared to its average volume of 3,021,320. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company has a 50-day moving average of $761.79 and a 200 day moving average of $666.06. The stock has a market cap of $696.95 billion, a P/E ratio of 126.47, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $380.77 and a 12-month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the prior year, the company posted $2.09 EPS. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. On average, research analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.